Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436697 | 1.00 | HRH3 (0.45) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL15975247 | 1.00 | HRH3 (0.45) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL9469827 | 0.98 | HRH3 (0.44) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL29381986 | 0.98 | HRH3 (0.44) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL9469820 | 0.98 | HRH3 (0.44) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| Acetic Acid SCHEMBL28749895 | 0.94 | HRH3 (0.42) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL26140843 | 0.93 | HRH3 (0.41) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL28492122 | 0.89 | HRH3 (0.51) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL186721 | 0.89 | HRH3 (0.51) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL1295721 | 0.89 | HRH3 (0.51) | HRH3MAPK1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | claimed |
| US-9682919-B2 | Small molecule inhibitors of Dusp6 and uses therefor | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-20 | — | — | US | claimed |
| US-20160355459-A1 | Small Molecule Inhibitors of Dusp6 and Uses Therefor | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2016-12-08 | — | — | US | claimed |
| US-9439877-B2 | Small molecule inhibitors of Dusp6 and uses therefor | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-09-13 | — | — | US | claimed |
| US-20160113889-A1 | Small Molecule Inhibitors of Dusp6 and Uses Therefor | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2016-04-28 | — | — | US | claimed |
| US-9127016-B2 | Small molecule inhibitors of Dusp6 and uses therefor | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-09-08 | — | — | US | claimed |
| US-20120122992-A1 | SMALL MOLECULE INHIBITORS OF Dusp6 AND USES THEREFOR | University of Pittsburgh-Of the Commonwealth Syste (US) | 2012-05-17 | — | — | US | claimed |
| WO-2010108058-A2 | SMALL MOLECULE INHIBITORS OF DUSP6 AND USES THEREFOR | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-09-23 | — | — | WO | claimed |
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4482527-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4482527-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-5691321-A | INSECTICIDES, MITICIDES, PARASITICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1997-11-25 | — | — | US | disclosed |
| CN-1148383-A | Heterocyclylamino-and heterocyclyloxy-cycloalkyl derivatives, their preparation and their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1997-04-23 | — | — | CN | disclosed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | disclosed |
| EP-0274234-B1 | SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | CCR2, CCRL2, CCR5 | HRH3 2104/4885MAPK1 3353/4885CHRM2 2936/4885 |
| US-20160113889-A1 | Small Molecule Inhibitors of Dusp6 and Uses Therefor | DUSP26, DUSP6, DUSP2 | HRH3 3943/4885MAPK1 122/4885CHRM2 4874/4885 |
| US-20160355459-A1 | Small Molecule Inhibitors of Dusp6 and Uses Therefor | DUSP26, DUSP6, DUSP2 | HRH3 3943/4885MAPK1 122/4885CHRM2 4874/4885 |
| US-20120122992-A1 | SMALL MOLECULE INHIBITORS OF Dusp6 AND USES THEREFOR | DUSP26, DUSP6, DUSP2 | HRH3 3943/4885MAPK1 122/4885CHRM2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.